Weight-loss supplements are rebranding as “GLP-1 boosters.” They’re nothing like Ozempic. If you had come across the ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Researchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

This is just a sneak peek at the thousands of consumer insights available to CivicScience clients. Discover more data. The ...

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

It may not sound surprising that treating obesity in adolescents and teens may have positive mental health impacts, but ...

Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

Baby Boomers looking to put new money to work may wish to check out the broader basket of dividend stocks while interest ...

Some private equity firms are pulling back from investing in consumer companies that could be negatively impacted by the ...